Information Provided By: 
Fly News Breaks for May 22, 2017
LJPC
May 22, 2017 | 07:35 EDT
SunTrust analyst Yatin Suneja says that the full data on La Jolla's CRH treatment, LJPC-501, should result in approval by the FDA because the drug met its primary endpoint. The analyst adds that he was "pleasantly surprised" by the drug's attainment of its " key secondary endpoint of CV SOFA score." Suneja says that the drug's failure to improve patients' total SOFA scores is "less relevant." He keeps a $57 price target and a Buy rating on the stock.
News For LJPC From the Last 2 Days
There are no results for your query LJPC
